{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:44:58Z","timestamp":1791387898148,"version":"4.3.3"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Acute bacterial skin and skin structure infections (ABSSSIs) are a significant source of morbidity in children. Dalbavancin, approved for the treatment of adults and children with ABSSSI, has a well-established safety profile in adults. We report safety and descriptive efficacy data for the treatment of ABSSSI in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Children with ABSSSI (birth\u2013&lt;18 years old) or sepsis (&lt;3 months old) known\/suspected to be caused by susceptible Gram-positive organisms were enrolled in this phase 3, multicenter, open-label, comparator-controlled study (NCT02814916). Children \u22653 months old were randomized 3:3:1 to receive single-dose dalbavancin, 2-dose dalbavancin, or a comparator antibiotic in 4 age cohorts; those &lt;3 months old received single-dose dalbavancin. Clinical response and microbiologic efficacy were evaluated 48\u201372 hours and 14, 28 and 54 days posttreatment. Bowel flora testing and audiology were collected in a subset of patients at baseline and day 28. Adverse events (AEs) were collected throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Treatment-emergent AEs occurred in 7.2%, 9.0% and 3.3% of patients in dalbavancin single-dose, dalbavancin 2-dose and comparator arms, respectively. Three serious AEs occurred in the dalbavancin single-dose arm; no treatment-related AEs, serious AEs, or AEs leading to study discontinuation were reported. Favorable clinical response at 48\u201372 hours was documented in 97.4%, 98.6% and 89.7% of patients. Safety and efficacy were comparable across age cohorts. The microbiologic intent-to-treat population had comparable clinical response for all baseline pathogens, including methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The safety profile of dalbavancin was consistent in children and adults with ABSSSI. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003798","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T16:00:20Z","timestamp":1670428820000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1097","volume":"42","author":[{"given":"Manana","family":"Giorgobiani","sequence":"first","affiliation":[{"name":"JSC Evex Hospitals, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret H.","family":"Burroughs","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Antadze","sequence":"additional","affiliation":[{"name":"JSC Evex Hospitals, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Carrothers","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Riccobene","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinal","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[{"name":"AbbVie Inc., Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penka","family":"Stefanova","sequence":"additional","affiliation":[{"name":"Medical University of Plovdiv and University Hospital \u201cSt. George,\u201d Plovdiv, Bulgaria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.pcl.2013.06.011","article-title":"Skin and soft tissue infections.","volume":"60","author":"Mistry","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1542\/peds.2012-0746","article-title":"Trends in resource utilization for hospitalized children with skin and soft tissue infections.","volume":"131","author":"Lopez","year":"2013","journal-title":"Pediatrics"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-14-296","article-title":"Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009.","volume":"14","author":"Suaya","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-13-252","article-title":"Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study.","volume":"13","author":"Ray","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"e52722","DOI":"10.1371\/journal.pone.0052722","article-title":"Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis.","volume":"8","author":"Dukic","year":"2013","journal-title":"PLoS One"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"491","DOI":"10.5811\/westjem.2014.4.20583","article-title":"Clinical management of skin and soft tissue infections in the U.S. emergency departments.","volume":"15","author":"Mistry","year":"2014","journal-title":"West J Emerg Med"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1469-0691.2012.03822.x","article-title":"USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus.","volume":"18","author":"Nimmo","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(06)68853-3","article-title":"Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.","volume":"368","author":"Grundmann","year":"2006","journal-title":"Lancet"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens.","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection.","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection.","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis.","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.","volume":"49","author":"Marbury","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age.","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age.","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20250614","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic target attainment analyses for dalbavancin in pediatric patients.","author":"Carrothers","year":"2022","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T20:03:44Z","timestamp":1749931424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003798","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}